Home > News > Liedekerke successfully completes EUR15 million medical device equity financing round for Cochlear Limited

NEWS

Liedekerke successfully completes EUR15 million medical device equity financing round for Cochlear Limited

calendar_new
16/11/2018

A team led by Corporate and Finance partner Christel Van den Eynden and Wim Dedecker successfully completed a EUR15 million investment for Australian listed hearing-device global leader Cochlear Limited, in the Belgium-based medical device company Nyxoah SA.

The start-up, founded 9 years ago in Mont-Saint-Guibert, is focused on developing and commercialising a hypoglossal nerve stimulation therapy for the treatment of OSA (Obstructive Sleep Apnea). Cochlear, which holds over two-third of the worldwide hearing implant market, is monitoring closely new growth markets and innovative technologies, and continues today its “investment journey” backing the Israeli-Belgian growing start-up with an investment which will help Nyxoah commercialise its nerve stimulation treatment, now that the start-up has just completed its BLAST-OSA clinical study and is awaiting its CE certification in order to be able to put its product on the EU market. Cochlear was named Australia's most innovative company in 2002 and 2003, and one of the world's most innovative companies by Forbes in 2011.


Intellectual Property Associates Erika Ellyne and Dorien Taeymans supported the Corporate team led by Head Christel Van den Eynden, and including Counsel Wim Dedecker, Partner Valérie Simonart, Associate Maurits Arnauw, and Junior Associate Jakob Mulier, to advise Cochlear.